Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
A patient presenting with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation is rare. We report a non-small cell lung cancer (NSCLC) patient with concomitant ALK rearrangement and exon 19 (E746-A750del) EGFR mutation. The ALK rearrangement was confirmed not only in the primary tumor biopsy specimen, but also in the pleural effusion cell block by reverse transcriptase-polymerase chain reaction (RT-PCR), Ventana ALK immunohistochemistry assay, and fluorescence in situ hybridization. No clinical benefit using chemotherapy or EGFR tyrosine kinase inhibitor gefitinib was obtained in this case.
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Jianya
J
Zhou
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Jing
J
Zheng
Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Jing
J
Zhao
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Yihong
Y
Sheng
Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Wei
W
Ding
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, China.
Jianying
J
Zhou
EGFR mutation; EML4–ALK; lung cancer; tyrosine kinase inhibitors